Back to today’s briefing

Story perspectives

FDA Rejects Skin Cancer Therapy Amid Leadership Turmoil

8/4/2025

25 4

Summary

Story summary

Ed Silverman examines the FDA's rejection of Replimune's skin cancer therapy, highlighting internal conflicts.
Leadership turmoil at the FDA impacted the decision, despite some staff backing the therapy.
Medicare recipients will experience delays in cancer drug price relief due to new provisions in the One Big Beautiful Bill Act.
The act limits price negotiations, risking over $5 billion in potential Medicare savings.

1 of 1

Story summary

Ed Silverman examines the FDA's rejection of Replimune's skin cancer therapy, highlighting internal conflicts.
Leadership turmoil at the FDA impacted the decision, despite some staff backing the therapy.
Medicare recipients will experience delays in cancer drug price relief due to new provisions in the One Big Beautiful Bill Act.
The act limits price negotiations, risking over $5 billion in potential Medicare savings.